Industry News/Prostate Cancer

Cancer Now Detected with 90 Percent Accuracy

Published in Cancer Weekly, April 10th, 1995

Horus Therapeutics, Inc., Rochester, New York, has completed development of a new blood test, ProstAsure, capable of detecting prostate cancer with 90 percent accuracy in clinical studies of more than 800 patients.

The most widely used test currently available is the combination of prostate specific antigen (PSA) and a digital rectal exam (DRE), which has a positive predictive value of only 48.5 percent in men over age 50.

Clinical experts in this field, such as Thomas A. Stamey, M.D. of the Department of Urology, Stanford University School of Medicine, agree that testing for prostate cancer should be done annually, as recommended by the American...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-04-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry